目的 探析二至丸联合雌二醇片/雌二醇地屈孕酮片复合包装治疗围绝经期综合征的临床效果。方法 选取2022年1月—2025年1月南通市中医院收治的80例围绝经期综合征患者，将患者按随机数字表法分为对照组和治疗组，每组各40例。对照组睡前温水送服雌二醇片/雌二醇地屈孕酮片复合包装，1次/d，前14 d每天口服1片白色片，后14 d每天口服1片灰色片。治疗组在对照组基础上早、晚饭后1 h温水送服二至丸，9 g/次。28 d为1个疗程，两组连续治疗3个疗程。比较两组的临床疗效、临床症状、子宫内膜厚度、生活质量、性激素指标。结果 治疗后，治疗组的总有效率为100.00%，高于对照组的总有效率85.00%（P＜0.05）。治疗后，两组患者改良Kupperman围绝经期妇女症状评分表（KMI）评分降低，子宫内膜厚度提高（P＜0.05），且治疗组KMI评分低于对照组，子宫内膜厚度高于对照组（P＜0.05）。治疗后，两组患者性生活、心理症状、血管舒缩症状、生理症状评分均降低（P＜0.05），且治疗组围绝经期生存质量量表（MEN-QOL）各维度评分均低于对照组（P＜0.05）。治疗后，两组患者血清卵泡刺激素（FSH）、黄体生成素（LH）水平均降低，血清雌二醇（E₂）水平升高（P＜0.05）；且治疗组血清FSH、LH水平低于对照组，血清E₂水平高于对照组（P＜0.05）。结论 围绝经期综合征患者经二至丸联合雌二醇片/雌二醇地屈孕酮片复合包装治疗后，不仅临床疗效更高，提高患者子宫内膜厚度，改善患者临床症状，还可以提高其生活质量，有效调节性激素水平，且不良反应发生率亦较低。

Objective To study the effect of Erzhi Pills combined with Estradiol Tablets/Estradiol Dydrogesterone Tablets Composite Packaging in treatment of perimenopausal syndrome. Methods A total of 80 patients with perimenopausal syndrome admitted to Nantong Hospital of Traditional Chinese Medicine from January 2022 to January 2025 were selected and divided into control group (40 cases) and treatment group (40 cases) according to the random number table method. The control group was po administered with Estradiol Tablets/Estradiol Dydrogesterone Tablets Composite Packaging with warm water before bedtime, at a dosage of 1 tablets daily. For the first 14 d, they took one white tablets daily, and for the next 14 days, one gray tablets daily. The treatment group received Erzhi Pills with warm water 1 h after breakfast and dinner in addition to the control group's regimen, 9 g per dose. One treatment course had 28 day, and two groups received three consecutive courses of treatment. The clinical efficacy, clinical symptoms, endometrial thickness, quality of life, and sex hormone indicators were compared between two groups. Results After treatment, the total effective rate of the treatment group was 100.00%, which was higher than the total effective rate of 85.00% in the control group (P < 0.05). After treatment, the KMI scores of two groups decreased, but the endometrial thickness increased (P < 0.05). The KMI score of the treatment group was lower than that of the control group, while the endometrial thickness was higher than that of the control group (P < 0.05). After treatment, the scores of sexual activity, psychological symptoms, vasomotor symptoms, and physiological symptoms in two groups decreased (P < 0.05), and the scores of each dimension of the MEN-QOL scale in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) decreased in two groups, while the serum level of estradiol (E₂) increased (P < 0.05). And the serum levels of FSH and LH in the treatment group were lower than those in the control group, while the serum level of E₂ was higher than that in the control group (P < 0.05). Conclusion Erzhi Pills combined with Estradiol Tablets/Estradiol Dydrogesterone Tablets Composite Packaging in treatment of perimenopausal syndrome can improve clinical efficacy, increase endometrial thickness, improve clinical symptoms, enhance quality of life, effectively regulate sex hormone levels, and have low adverse reactions.

R984